Please assess the completion status of the following clinical trial:

Trial Title: Orlistat/Phentermine Versus Placebo/Phentermine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* After a screening test, the characteristics of the trial were explained and then the patient voluntarily agreed to participate in the study and signed a consent form with IRB approval.~* Adults over 20 years of age at the time of obtaining consent~* A back pain score of 3 and a metabolic risk of a BMI greater than 27 kg / m2.~* Metabolic risk includes the following, according to the American Endocrinology Society (AACE) guidelines. (Diabetic stage, metabolic syndrome, type 2 diabetes, dyslipidemia, hypertension, cardiovascular disease, nonalcoholic fatty liver, polycystic ovary syndrome, obstructive sleep apnea, osteoarthritis, gastroesophageal~* In the case of a pregnant woman, pregnancy test is negative~* Patients who can understand and speak Korean~* Patients whose physicians approved to participate in the study~* Patients who are able to complete the study without participating in other intervention studies (drug, diet, exercise intervention studies) during the study period.~* Patients who agreed to contraception during the study~Exclusion Criteria:~1. Persons who are contraindicated for Phentermine Sympathomized excitable amines sensitive patients or patients with specific qualities Progressive arteriosclerosis patients Patients with symptomatic cardiovascular disease When there is pulmonary hypertension or heart valve disease A patient with hyperthyroidism A patient with glaucoma Patients who are extremely anxious or excited mentally person who had history of drug abuse Patients taking other central nervous system stimulants or those 14 days after the administration of MAO inhibitors (MAOIs)~2. Persons who are contraindicated for Orlistat Patient with chronic malabsorption syndrome or patient who stops secretion of juice Patients with hypersensitivity to this or this component~3. Uncontrolled hypertenstion (SBP\>180mmHg or DBP \>120mmHg)~4. Under taking anti-diabetics or fasting blood glucose \>=200mg/dl~5. If your weight has decreased by more than 5 kg in the last 3 months~6. (AST or ALT\> 3 times the normal value) or kidney disease (serum creatinine\> 2.0 mg / dL)~7. Patients taking other clinical trial drugs~8. Patients taking other appetite suppressants within the last 30 days~9. Acute infectious diseases such as pneumonia, acute enteritis, and acute urinary tract infections~10. If you are participating in other clinical trials~11. Those who are deemed unsuitable for participating in this study by the researcher

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- orlistat (Type: EXPERIMENTAL): Orlistat 120Mg Cap (120mg, three times a day, within 1hour after meal) combined with phentermine pill (37.5mg, once a day, within 1hour after meal)
- placebo (Type: PLACEBO_COMPARATOR): placebo (120mg, three times a day, within 1hour after meal) combined with phentermine pill (37.5mg, once a day, within 1hour after meal)

Based on this trial design, predict the completion outcome and termination type (if applicable).